FGFR inhibition blocks NF-ĸB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma.

Saved in:
Bibliographic Details
Title: FGFR inhibition blocks NF-ĸB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma.
Authors: Zhen Y; Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA, USA.; Dept. of Medicine, Harvard Medical School, Boston, MA, USA.; The Cancer Program, Broad Institute, Cambridge, MA, USA., Liu K; Center for Computational and Integrative Biology, Department of Molecular Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Shi L; Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA, USA.; Dept. of Medicine, Harvard Medical School, Boston, MA, USA.; The Cancer Program, Broad Institute, Cambridge, MA, USA., Shah S; Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA., Xu Q; Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA, USA.; Dept. of Medicine, Harvard Medical School, Boston, MA, USA.; The Cancer Program, Broad Institute, Cambridge, MA, USA., Ellis H; Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA, USA.; Dept. of Medicine, Harvard Medical School, Boston, MA, USA.; The Cancer Program, Broad Institute, Cambridge, MA, USA., Balasooriya ER; Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA, USA.; Dept. of Medicine, Harvard Medical School, Boston, MA, USA.; The Cancer Program, Broad Institute, Cambridge, MA, USA., Kreuzer J; Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.; Dept. of Medicine, Harvard Medical School, Boston, MA, USA., Morris R; Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA., Baldwin AS; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, USA., Juric D; Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.; Dept. of Medicine, Harvard Medical School, Boston, MA, USA., Haas W; Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.; Dept. of Medicine, Harvard Medical School, Boston, MA, USA., Bardeesy N; Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA. Bardeesy.Nabeel@mgh.harvard.edu.; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA, USA. Bardeesy.Nabeel@mgh.harvard.edu.; Dept. of Medicine, Harvard Medical School, Boston, MA, USA. Bardeesy.Nabeel@mgh.harvard.edu.; The Cancer Program, Broad Institute, Cambridge, MA, USA. Bardeesy.Nabeel@mgh.harvard.edu.
Source: Nature communications [Nat Commun] 2024 May 07; Vol. 15 (1), pp. 3805. Date of Electronic Publication: 2024 May 07.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2041-1723
DOI:10.1038/s41467-024-47514-y